Summary

Global Direct-acting Antiviral Drug Market was valued at USD 11.41 Billion in 2024 and is expected to reach USD 23.61 Billion in the forecast period with a CAGR of 12.86% through 2030. The global direct-acting antiviral (DAA) drug market is expanding due to the increasing prevalence of viral infections, particularly hepatitis C. These drugs target specific viral proteins to inhibit replication, offering a highly effective and well-tolerated treatment option. Pharmaceutical advancements have led to the development of next-generation DAAs with improved efficacy and shorter treatment durations. The market is witnessing significant growth as healthcare providers and governments prioritize hepatitis C elimination programs. The introduction of combination therapies has further enhanced treatment outcomes, reducing the risk of drug resistance and increasing sustained virologic response (SVR) rates. Expanding access to diagnostic testing and treatment in developing countries is playing a crucial role in market expansion.
The market is benefiting from increasing awareness of early diagnosis and treatment, supported by government initiatives and non-profit organizations. Rising investments in antiviral drug research are fostering the development of innovative therapies with improved safety profiles. The shift toward personalized medicine is influencing the demand for targeted antiviral therapies, ensuring higher treatment success rates. Breakthroughs in biotechnology and genetic research are enabling pharmaceutical companies to design more precise and potent DAAs. The growing preference for oral therapies over injectable treatments is driving patient adherence, making DAAs a preferred choice in antiviral treatment strategies. Collaborations between research institutions and pharmaceutical firms are expediting drug development, leading to a robust pipeline of next-generation DAAs. Expanding healthcare infrastructure and favorable reimbursement policies in various countries are creating opportunities for market players.
Despite advancements, the market faces challenges related to high treatment costs, limiting accessibility for patients in low-income regions. The emergence of drug-resistant viral strains is a growing concern, requiring continuous research to develop more effective formulations. Regulatory hurdles and lengthy approval processes for new DAAs can delay market entry, impacting innovation cycles. Limited awareness in certain regions about the availability of effective antiviral treatments is slowing adoption rates. The presence of generic alternatives is intensifying market competition, putting pressure on pricing strategies. Addressing these challenges through strategic pricing models, research in resistance management, and increased global treatment outreach will be essential for sustaining market growth.
Key Market Drivers
High Efficacy and Improved Cure Rates
In recent years, the global pharmaceutical landscape has witnessed a transformative shift in the treatment of viral infections, particularly hepatitis C, due to the advent of direct-acting antiviral drugs (DAAs). These innovative medications have demonstrated exceptional efficacy, with cure rates exceeding 95%, redefining the approach to managing viral diseases.
The high efficacy of DAAs translates into significantly improved patient outcomes. For instance, a study published in JAMA Network Open reported that among patients treated with DAAs, 97.3% achieved sustained virologic response (SVR), indicating a cure. Successful DAA therapy not only clears the virus but also halts disease progression, reducing risks of liver fibrosis, cirrhosis, and hepatocellular carcinoma.
Beyond individual benefits, DAAs contribute to public health by reducing viral transmission. Effective treatment decreases viral load, thereby lowering the likelihood of spreading infections such as hepatitis B and C, which are transmitted through routes like blood contact and sexual intercourse. The World Health Organization highlights that DAAs can cure over 95% of hepatitis C cases, yet access to diagnosis and treatment remains limited globally.
DAAs also offer shorter treatment durations compared to traditional interferon-based therapies. While older regimens required treatment courses of up to 48 weeks, DAA therapies typically range from 8 to 12 weeks, enhancing patient compliance and reducing healthcare burdens. Furthermore, DAAs are associated with improved tolerability and fewer severe side effects, encouraging patients to complete their treatment regimens.
The success of DAAs has instilled confidence among patients and healthcare providers. For example, the U.S. Department of Health and Human Services notes that new hepatitis C treatments can cure approximately 95% of patients, significantly decreasing the likelihood of severe liver complications and reducing overall healthcare costs. This underscores the importance of expanding access to these life-saving therapies to achieve broader public health benefits.
Key Market Challenges
High Treatment Costs
One of the most significant challenges is the high cost of direct-acting antiviral drugs. While these medications are highly effective, their price tags can be prohibitive for many patients, especially in low- and middle-income countries. Striking a balance between recouping research and development costs and ensuring affordable access is a persistent challenge.
Key Market Trends
Expanded Indications
One significant trend in the DAA market is the exploration of expanded indications. While DAAs have been predominantly used to treat hepatitis C and B, researchers are investigating their efficacy against other viral infections. This could lead to the development of new DAA therapies targeting a broader range of viruses.
Key Market Players
• Natco Pharma Ltd
• Vertex Pharmaceuticals Inc
• Dr Reddy's Laboratories Ltd
• Johnson & Johnson
• Merck & Co Inc
• Gilead Sciences Inc
• AbbVie Inc
• Bristol-Myers Squibb Co
Report Scope:
In this report, the Global Direct-acting Antiviral Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Direct-acting Antiviral Drug Market, By Type:
o NS3/4A Protease
o NS5A Protein
o NS5B RNA-Dependent RNA polymerase
• Direct-acting Antiviral Drug Market, By Indication:
o Hepatitis C Virus
o HIV Infection/ AIDS
o Influenza
o Prophylaxis
• Direct-acting Antiviral Drug Market, By Route:
o Intravenous
o Oral
o Subcutaneous
o Topical
• Direct-acting Antiviral Drug Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Direct-acting Antiviral Drug Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ Germany
§ United Kingdom
§ France
§ Italy
§ Spain
o Asia-Pacific
§ China
§ Japan
§ India
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Direct-acting Antiviral Drug Market.
Available Customizations:
Global Direct-acting Antiviral Drug market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Direct-acting Antiviral Drug Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
5.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
5.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Product Market Map
5.3.1. By Drug Type
5.3.2. By Indication
5.3.3. By Route
5.3.4. By Distribution Channel
5.3.5. By Region
6. North America Direct-acting Antiviral Drug Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
6.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
6.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Direct-acting Antiviral Drug Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Type
6.3.1.2.2. By Indication
6.3.1.2.3. By Route
6.3.1.2.4. By Distribution Channel
6.3.2. Canada Direct-acting Antiviral Drug Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Type
6.3.2.2.2. By Indication
6.3.2.2.3. By Route
6.3.2.2.4. By Distribution Channel
6.3.3. Mexico Direct-acting Antiviral Drug Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Type
6.3.3.2.2. By Indication
6.3.3.2.3. By Route
6.3.3.2.4. By Distribution Channel
7. Europe Direct-acting Antiviral Drug Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
7.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
7.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
7.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Direct-acting Antiviral Drug Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Type
7.3.1.2.2. By Indication
7.3.1.2.3. By Route
7.3.1.2.4. By Distribution Channel
7.3.2. United Kingdom Direct-acting Antiviral Drug Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Type
7.3.2.2.2. By Indication
7.3.2.2.3. By Route
7.3.2.2.4. By Distribution Channel
7.3.3. France Direct-acting Antiviral Drug Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Type
7.3.3.2.2. By Indication
7.3.3.2.3. By Route
7.3.3.2.4. By Distribution Channel
7.3.4. Italy Direct-acting Antiviral Drug Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Type
7.3.4.2.2. By Indication
7.3.4.2.3. By Route
7.3.4.2.4. By Distribution Channel
7.3.5. Spain Direct-acting Antiviral Drug Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Type
7.3.5.2.2. By Indication
7.3.5.2.3. By Route
7.3.5.2.4. By Distribution Channel
8. Asia-Pacific Direct-acting Antiviral Drug Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
8.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
8.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
8.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Direct-acting Antiviral Drug Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Type
8.3.1.2.2. By Indication
8.3.1.2.3. By Route
8.3.1.2.4. By Distribution Channel
8.3.2. Japan Direct-acting Antiviral Drug Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Type
8.3.2.2.2. By Indication
8.3.2.2.3. By Route
8.3.2.2.4. By Distribution Channel
8.3.3. India Direct-acting Antiviral Drug Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Type
8.3.3.2.2. By Indication
8.3.3.2.3. By Route
8.3.3.2.4. By Distribution Channel
8.3.4. Australia Direct-acting Antiviral Drug Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Type
8.3.4.2.2. By Indication
8.3.4.2.3. By Route
8.3.4.2.4. By Distribution Channel
8.3.5. South Korea Direct-acting Antiviral Drug Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Type
8.3.5.2.2. By Indication
8.3.5.2.3. By Route
8.3.5.2.4. By Distribution Channel
9. South America Direct-acting Antiviral Drug Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
9.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
9.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
9.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Direct-acting Antiviral Drug Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Type
9.3.1.2.2. By Indication
9.3.1.2.3. By Route
9.3.1.2.4. By Distribution Channel
9.3.2. Argentina Direct-acting Antiviral Drug Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Type
9.3.2.2.2. By Indication
9.3.2.2.3. By Route
9.3.2.2.4. By Distribution Channel
9.3.3. Colombia Direct-acting Antiviral Drug Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Type
9.3.3.2.2. By Indication
9.3.3.2.3. By Route
9.3.3.2.4. By Distribution Channel
10. Middle East and Africa Direct-acting Antiviral Drug Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
10.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
10.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
10.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Direct-acting Antiviral Drug Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Type
10.3.1.2.2. By Indication
10.3.1.2.3. By Route
10.3.1.2.4. By Distribution Channel
10.3.2. Saudi Arabia Direct-acting Antiviral Drug Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Type
10.3.2.2.2. By Indication
10.3.2.2.3. By Route
10.3.2.2.4. By Distribution Channel
10.3.3. UAE Direct-acting Antiviral Drug Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Type
10.3.3.2.2. By Indication
10.3.3.2.3. By Route
10.3.3.2.4. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. Competitive Landscape
14.6.1. Natco Pharma Ltd
14.6.2. Vertex Pharmaceuticals Inc
14.6.3. Dr Reddy's Laboratories Ltd
14.6.4. Johnson & Johnson
14.6.5. Merck & Co Inc
14.6.6. Gilead Sciences Inc
14.6.7. AbbVie Inc
14.6.8. Bristol-Myers Squibb Co
15. Strategic Recommendations
16. About Us & Disclaimer